SEC Form 4 filed by Director Hagemann Robert

$ZBH
Industrial Specialties
Health Care
Get the next $ZBH alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HAGEMANN ROBERT

(Last) (First) (Middle)
345 E. MAIN STREET

(Street)
WARSAW IN 46580

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units(1) $107.76(2) 09/30/2024 A 313.196 (3) (3) Common Stock 313.196 $0 28,851.426(4) D
Explanation of Responses:
1. The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
2. The Conversion or Exercise Price of Derivative Security is 1-for-1.
3. Units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
4. Includes 60.573 phantom stock units accrued on July 31, 2024 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
/s/ Chad F. Phipps, Attorney-in-Fact for Robert A. Hagemann (power of attorney previously filed) 10/02/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ZBH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ZBH

DatePrice TargetRatingAnalyst
12/17/2024$125.00 → $128.00Neutral → Overweight
Analyst
9/10/2024Peer Perform
Wolfe Research
7/1/2024$140.00 → $115.00Overweight → Neutral
Piper Sandler
5/30/2024$129.00Neutral
Goldman
5/21/2024$150.00Hold → Buy
Argus
1/4/2024$135.00 → $125.00Outperform → In-line
Evercore ISI
10/20/2023$120.00Neutral
ROTH MKM
8/28/2023$139.00Neutral → Buy
BTIG Research
More analyst ratings

$ZBH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

    Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basisFourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basisFull-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.  The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over

    $FNA
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties
  • Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28

    Demonstrates Zimmer Biomet's Commitment to Investing in Higher GrowthEnd-Markets, with Expansion into ~$5 Billion Foot and Ankle Segment Expected to Enhance Zimmer Biomet's Financial Profile; Immediately Accretive to Revenue Growth and Accretive to Adjusted EPS within 24 Months of Deal Close WARSAW, Ind. and ENGLEWOOD, Colo., Jan. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Paragon 28, Inc. (NYSE:FNA), a leading medical device company focused exclusively on the foot and ankle orthopedic segment, today announced they have entered into a definitive agreement for Zimmer Biomet to acquire all outstanding shares of common sto

    $FNA
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties
  • Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2024 Financial Results

    WARSAW, Ind., Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m. ET.  A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com.  It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may d

    $ZBH
    Industrial Specialties
    Health Care

$ZBH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ZBH
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$ZBH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ZBH
SEC Filings

See more

$ZBH
Leadership Updates

Live Leadership Updates

See more
  • Zimmer Biomet Welcomes Arnold Schwarzenegger as Chief Movement Officer

    Schwarzenegger to Inspire a Bold New Era of Well-being, Active Living and Reinvention to Advance Company's Mission to Alleviate Pain and Improve the Quality of Life for People Around the World WARSAW, Ind., Nov. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a partnership with Arnold Schwarzenegger, who will take on the newly established role of Chief Movement Officer. In this strategic role, Schwarzenegger will collaborate closely with Zimmer Biomet to motivate, engage and support individuals to increase mobility, maintain joint health and proactively incorporate movement into their daily routines to foster over

    $ZBH
    Industrial Specialties
    Health Care
  • Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

    WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.  "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the

    $EMBC
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties
  • Zimmer Biomet Announces Appointment of Louis A. Shapiro to Board of Directors

    WARSAW, Ind., Jan. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Louis A. Shapiro, formerly the President and Chief Executive Officer of the Hospital for Special Surgery (HSS), has been appointed to the Board, effective immediately. HSS has been recognized as a leading academic medical center focused on musculoskeletal health – it was ranked #1 in U.S. orthopedics hospitals for 14 years in a row by U.S. News & World Report and #1 in worldwide orthopedics hospitals by Newsweek for the past four consecutive years. Founded in 1863, HSS is the oldest orthopedics hospital in the U.S., performs more than 40,000 su

    $ZBH
    Industrial Specialties
    Health Care

$ZBH
Financials

Live finance-specific insights

See more
  • Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

    Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basisFourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basisFull-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.  The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over

    $FNA
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties
  • Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2024 Financial Results

    WARSAW, Ind., Jan. 16, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 6, 2025 at 8:30 a.m. ET.  A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com.  It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may d

    $ZBH
    Industrial Specialties
    Health Care
  • Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2024

    WARSAW, Ind., Dec. 18, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2024. The cash dividend of $0.24 per share is payable on or about January 31, 2025 to stockholders of record as of the close of business on December 30, 2024. About Zimmer Biomet  Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health.

    $ZBH
    Industrial Specialties
    Health Care

$ZBH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more